Cardioprotective effects of lipoic acid, quercetin and resveratrol on oxidative stress related to thyroid hormone alterations in long-term obesity

Cheserek, Maureen Jepkorir; Wu, Guangdong; Li, Longnan; Li, Lirong; Karangwa, Eric; Shi, Yonghui; Li, Guowei

doi:10.1016/j.jnutbio.2016.02.008

Cited by 36 publications

(22 citation statements)

References 49 publications

(72 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Firstly, well-known anti-oxidant properties of quercetin and (-)-epicatechin provide the protection of cellular macromolecules from damages and predict the mitochondrial dysfunction (Khan et al, 2016). In this way, studied drugs demonstrated benefit action against the development of aging-related pathologies including neurodegeneration (Shay et al, 2015; Barreca et al, 2016; Elumalai and Lakshmi, 2016), cardiovascular and liver diseases (Ansar et al, 2016; Cheserek et al, 2016), diabetes (Shay et al, 2015; Haddad and Eid, 2016), cancer (Shay et al, 2015; Khan et al, 2016). …”

Section: Discussionmentioning

confidence: 99%

Geroprotective and Radioprotective Activity of Quercetin, (-)-Epicatechin, and Ibuprofen in Drosophila melanogaster

et al. 2016

View full text Add to dashboard Cite

The modulation of longevity genes and aging-associated signaling pathways using pharmacological agents is one of the potential ways to prolong the lifespan and increase the vitality of an organism. Phytochemicals flavonoids and non-steroidal anti-inflammatory drugs have a large potential as geroprotectors. The goal of the present study was to investigate the effects of long-term and short-term consumption of quercetin, (-)-epicatechin, and ibuprofen on the lifespan, resistance to stress factors (paraquat, hyperthermia, γ-radiation, and starvation), as well as age-dependent physiological parameters (locomotor activity and fecundity) of Drosophila melanogaster. The long-term treatment with quercetin and (-)-epicatechin didn't change or decreased the lifespan of males and females. In contrast, the short-term treatment with flavonoids had a beneficial effect and stimulated the resistance to paraquat and acute γ-irradiation. The short-term ibuprofen consumption had a positive effect on the lifespan of females when it was carried out at the middle age (30–40 days), and to the survival of flies under conditions of oxidative and genotoxic stresses. However, it didn't change the lifespan of males and females after the treatment during first 10 days of an imago life. Additionally, quercetin, (-)-epicatechin, and ibuprofen decreased the spontaneous locomotor activity of males, but had no effect of stimulated the physical activity and fecundity of females. Revealed quercetin, (-)-epicatechin, and ibuprofen activity can be associated with the stimulation of stress response mechanisms through the activation of pro-longevity pathways, or the induction of hormesis.

show abstract

Section: Discussionmentioning

confidence: 99%

Geroprotective and Radioprotective Activity of Quercetin, (-)-Epicatechin, and Ibuprofen in Drosophila melanogaster

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In addition, resveratrol protected against sarcopenic obesity by improving mitochondrial function and reducing oxidative stress through the PKA/liver kinase B1 (LKB1)/AMPK pathway [100]. Resveratrol also showed positive impacts on obesity-related complications, such as reproductive dysfunction like infertility and endocrine disorders [101,102]. To summarize, resveratrol has been illustrated to decrease body weight, regulate lipid deposition, modulate adipocyte gene expression, and promote white adipose browning, via PI3K/SIRT1, Nrf2, PPAR-γ, TNF-α, and PKA/LKB1/AMPK signaling pathways ( Table 2).…”

Section: Obesitymentioning

confidence: 99%

Health Benefits and Molecular Mechanisms of Resveratrol: A Narrative Review

Meng

Zhou

Zhao

et al. 2020

Foods

207

144

View full text Add to dashboard Cite

Resveratrol is a bioactive compound in many foods. Since its anticancer activity was reported in 1997, its health benefits have been intensively investigated. Resveratrol has antioxidant, anti-inflammatory, immunomodulatory, glucose and lipid regulatory, neuroprotective, and cardiovascular protective effects, therefore, can protect against diverse chronic diseases, such as cardiovascular diseases (CVDs), cancer, liver diseases, obesity, diabetes, Alzheimer's disease, and Parkinson's disease. This review summarizes the main findings of resveratrol-related health benefits in recent epidemiological surveys, experimental studies, and clinical trials, highlighting its related molecular mechanisms. Resveratrol, therefore, has been regarded as a potent candidate for the development of nutraceuticals and pharmaceuticals to prevent and treat certain chronic diseases. Foods 2020, 9, 340 Iranian (Tehranian)/Iran Cross-sectional study, part of the TLG study N = 2618 (male, 1162; female, 1456) Quartiles: Q1: 0.014 mg/day Q2: 0.015-0.027 mg/day Q3: 0.028-0.053 mg/day Q4: 0.054 mg/day (FFQ on a daily frequency, 1 year prior) Null: Significantly associated with WC, TG, HDL, BG, and MS Unfavorable: The top quantile of intake (0.054 mg/day and more) was positively associated with high BP (HR = 1.52; 95% CI: 1.02-2.27) [19] Spanish/Spain Cross-sectional study, part of the PREDIMED study N = 1000 (male, 479; female, 521) Quintiles: Q1: 0.48 mg/day Q2: 1.04 mg/day Q3: 2.04 mg/day Q4: 5.75 mg/day (FFQ, 1 year prior) Favorable: Significantly decreased CVD risk factors (FBG (95% CI: −1.033 to −0.033); TG (95% CI: −1.998 to −0.029); and heart rate (95% CI: −0.467 to −0.087)). Null: Resveratrol intake was not significantly associated with TC, HDL, LDL and BP [6] Spanish/Spain Cross-sectional study, part of the PREDIMED study N = 7172 (male, 3249; female, 3923) Quintiles: Q1: 0.48 mg/d Q2: 1.04 mg/d Q3: 2.04 mg/day Q4: 5.75 mg/day (FFQ, 1 year prior) Favorable: High dose intake (5.75 mg/d) significantly reduced all-cause mortality by 52% (HR = 0.48; 95% CI: 0.25-0.91) Null: No significant CVD risk reduction (HR = 0.77; 95% CI: 0.35-1.72) [21,22] Swedish/Sweden Case-control study N = 1400 (case, 594 including (OAC, 181; OSCC, 158; JAC, 255)) (control, 806) Control: 0.1 mg/day OAC: 0.07 mg/day OSCC: 0.11 mg/day JAC: 0.09 mg/day (FFQ, 20 years prior) Favorable: In a significantly negative association with the risk of 3 subtypes of esophageal cancer (OAC (95% CI: 0.12-0.49); OSCC (95% CI: 0.15-0.65), and JAC (95% CI: 0.28-0.84)) [5] Italian/Italy Cohort study, "Aging in the Chianti Region" N = 529 (male, 236; female, 293) Tertiles: T1: 0.1 mg/day T2: 0.1-1.1 mg/day T3: >1.1 mg/day (FFQ) Favorable: Inversely associated with the risk of frailty syndrome during the first 3-year follow-up (T3 vs. T1: OR = 0.11; 95% CI: 0.03-0.45) Null: No substantial association with (i) risk of frailty syndrome in 6-, or 9-year follow-up; (ii) inflammatory biomarkers including IL-6, IL-1β, TNF-α, and CRP; (iii) CVD, cancer or all-cause mortality [18] Chinese/Chin...

show abstract

“…The question was raised whether quercetin might adversely affect thyroid function, based on in vitro studies showing an inhibition of thyroid peroxidase, the thyroid type 1 deiodinase and of the expression of thyroid‐restricted genes by quercetin as well as based on a rat study showing a decrease in radioiodine uptake into the thyroid after intraperitoneally applied quercetin (50 mg kg –1 bw per day for 14 d) . However, in studies involving oral application of quercetin, adverse effects on thyroid hormone levels were not observed in animal models for obesity and hypothyroidism at quercetin doses between 10 and 25 mg kg –1 bw per day for 2–6 months or in chronic toxicity studies in rats investigating histopathological effects on the thyroid gland at quercetin doses of up to 2000 mg kg –1 bw per day …”

Section: Safety Aspectsmentioning

confidence: 99%

Safety Aspects of the Use of Quercetin as a Dietary Supplement

Andres

Pevny

Ziegenhagen

et al. 2017

Molecular Nutrition Food Res

386

246

View full text Add to dashboard Cite

The flavonoid quercetin is frequently found in low amounts as a secondary plant metabolite in fruits and vegetables. Isolated quercetin is also marketed as a dietary supplement, mostly as the free quercetin aglycone, and frequently in daily doses of up to 1000 mg d -1 exceeding usual dietary intake levels. The present review is dedicated to safety aspects of isolated quercetin used as single compound in dietary supplements. Among the numerous published human intervention studies, adverse effects following supplemental quercetin intake have been rarely reported and any such effects were mild in nature. Published adequate scientific data for safety assessment in regard to the long-term use (>12 weeks) of high supplemental quercetin doses (ࣙ1000 mg) are currently not available. Based on animal studies involving oral quercetin application some possible critical safety aspects could be identified such as the potential of quercetin to enhance nephrotoxic effects in the predamaged kidney or to promote tumor development especially in estrogen-dependent cancer. Furthermore, animal and human studies with single time or short-term supplemental quercetin application revealed interactions between quercetin and certain drugs leading to altered drug bioavailability. Based on these results, some potential risk groups are discussed in the present review.

show abstract

Cardioprotective effects of lipoic acid, quercetin and resveratrol on oxidative stress related to thyroid hormone alterations in long-term obesity

Cited by 36 publications

References 49 publications

Geroprotective and Radioprotective Activity of Quercetin, (-)-Epicatechin, and Ibuprofen in Drosophila melanogaster

Geroprotective and Radioprotective Activity of Quercetin, (-)-Epicatechin, and Ibuprofen in Drosophila melanogaster

Health Benefits and Molecular Mechanisms of Resveratrol: A Narrative Review

Safety Aspects of the Use of Quercetin as a Dietary Supplement

Contact Info

Product

Resources

About